Across TCGA pan-cancer cohorts, IRF9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IRF9 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IRF9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IRF9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where IRF9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.893	0.364	.004	31	view →
HNSC	OS	Median	All	1.000	0.449	.023	14	view →
PDAC	OS	Median	III,IV	0.165	0.590	.002	13	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	8	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IRF9 tumor-vs-normal RNA expression · all IRF9 data types